DelveInsight’s “Actinic Keratosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Actinic Keratosis , historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the report 1. The United States had the highest Actinic Keratosis prevalence with 66,733,101 cases in 2017. 2. The male-to-female ratios of Actinic Keratosis patients differ among various countries, but a male excess is a consistent finding among all countries except Italy. 3. Among the EU5 countries, Germany had the highest Actinic Keratosis prevalent population with 8,294,972 cases followed by the United Kingdom with a prevalent population of 5,419,455 in 2017. On the other hand, Japan has the lowest prevalent population with 700,954 cases in 2017.
“Actinic Keratosis prevalence is higher among men than women of the same age.”
Request for sample pages: https://www.delveinsight.com/sample-request/actinic-keratosis-market
The launch of the emerging therapies is expected to significantly impact Actinic Keratosis treatment scenario in the upcoming years:- Drugs covered 1. KX01 Ointment 2. VDA-1102 3. SOR 007 And many others
The key players in Actinic Keratosis market are: 1. Athenex 2. Vidac Pharma 3. DFB Soria
And many others
Table of contents
1. Key Insights 2. Executive Summary of Actinic Keratosis 3. Actinic Keratosis Market Overview at a Glance 4. Actinic Keratosis Disease Background and Overview 5. Actinic Keratosis Epidemiology and Patient Population 6. Country Wise-Epidemiology of Actinic Keratosis Disease 6.1. United States 6.2. EU5 Countries 6.3. Germany 6.4. France 6.5. Italy 6.6. Spain 6.7. United Kingdom 6.8. Japan 7. Actinic Keratosis Treatment Practices 8. Current Unmet Needs 9. Actinic Keratosis Marketed Drugs 9.1. Aldara: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals) 9.2. Zyclara: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals) 9.3. Solaraze: Sandoz Pharmaceuticals 9.4. Efudex: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals) 9.5. Carac: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals) 9.6. Picato: LEO Pharma 9.7. Actikerell: Almirall S.A. 9.8. Fluoroplex: Aqua Pharmaceuticals 9.9. Ameluz: Biofrontera 9.10.Metvixia: Galderma 9.11.Levulan Kerastick: DUSA Pharmaceuticals 9.12.Alacare: Photonamic GmbH & Co. KG 9.13.Eryfotona AK-NMSC SPF 100+ Fluid: ISDIN Corp 10. Key Cross Competition 11. Actinic Keratosis Emerging Drugs 11.1.KX01 Ointment: Athenex 11.2.VDA-1102: Vidac Pharma 11.3.SOR 007: DFB Soria 12. Actinic Keratosis 7 Major Market Analysis 13. The United States Market Outlook of Actinic Keratosis 14. EU-5 Countries: Market Outlook 15. Germany Market outlook of Actinic Keratosis 16. France Market outlook of Actinic Keratosis 17. Italy Market outlook of Actinic Keratosis 18. Spain Market outlook of Actinic Keratosis 19. United Kingdom Market outlook of Actinic Keratosis 20. Japan Market outlook of Actinic Keratosis 21. Market Drivers 22. Market Barriers 23. SWOT Analysis 24. Reimbursement 25. KOL Views 26. Appendix 27. DelveInsight Capabilities 28. Disclaimer 29. About DelveInsight
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/